In conclusion, GLP-1 receptor agonists represented by dulaglutide or semaglutide can not only reduce glycosylated hemoglobin and fasting blood glucose levels in overweight or obese patients with type 2 diabetes, but also improve BMI. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.